Uncategorized

Ankyra Therapeutics presented preliminary data from an exploratory Phase 1 canine clinical study evaluating cANK-101, a canine IL-12 anchored therapeutic, to treat advanced malignant melanoma.

Aulos Bioscienc presented new pharmacodynamic data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of AU-007, the first human monoclonal antibody designed using artificial intelligence to be tested in a clinical trial.

Puma Biotechnology, Inc. announced the poster presentation of a Phase I/II trial of alisertib plus pembrolizumab for the treatment of patients with Rb-deficient head and neck squamous cell carcinoma at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, Massachusetts.

The next frontier in RNA therapies, RNA editing has the potential to treat both genetic and common disorders, and the technology is rapidly expanding beyond the liver.

The FDA is gearing up for six decisions in the next two weeks, two of which involve highly anticipated medicines for rare diseases.

Recomendaciones del Royal College of Physicians del Reino Unido para adultos de atención primaria y secundaria.

About 42% of Medicare Advantage plans that offer prescription drug coverage in 2024 earned four or more stars, compared with just over half this year.   

The European Commission ordered the gene sequencing company to support Grail with two-and-a-half years of funding if it pursues a spinoff.

The health system and unions have been negotiating for seven months in pursuit of a new contract. On Friday, they announced a deal.

Un estudio confirma que el verano de 2022 fue el más caluroso en España de los últimos 700 años. Y que España es uno de los países más afectados por el cambio climático global.   El estudio lo ha llevado a cabo un equipo internacional en …